Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2003

View Archived Issues

Disappointing results for proof-of concept trial of VI-0162 in PE

Good safety and pharmacokinetic profile reported for rhFXIII in healthy volunteers

Esperion updates clinical development progress

Tularik highlights Q2 achievements

Oral direct thrombin inhibitors for the prevention of thrombosis after hip replacement surgery

Keppra oral solution approved for epilepsy

Synergistic prevention of arterial thrombosis reported for aspirin and CS-747 in preclinical studies

ArQule signs agreement to acquire Cyclis

Three related series of PPARalpha agonists patented by AstraZeneca researchers

Novel CCR4 receptor modulators for asthma therapy under study at AstraZeneca

New metabolically stable antiandrogens prepared and tested at Chugai

Lundbeck presents new NK2 antagonists with utility in psychiatric disorders

Kyowa Hakko and Fuji researchers identify 1,3,4-thiadiazole-based antitumor agents

Novel FTase inhibitors in early development at Janssen

AstraZeneca presents novel analgesic bradykinin B2 antagonists

Zentaris prepares and tests new GnRH antagonists

Potential role suggested for LB-30870 in the prophylaxis and prevention of thrombosis

Orally active taxane derivative MAC-321 demonstrates broad therapeutic potential

Antiangiogenic MMP inhibitor designed at Kolon

Early completion anticipated for pivotal R-1549 trial

Promising preclinical data reported for novel histone deacetylase inhibitor

Topamax safety information updated

BTG to evaluate BGC-9331 as a first-line treatment for gastric cancer

New low doses of Premarin approved for prevention of postmenopausal osteoporosis

Selective CDK inhibitor JNJ-7706621 as potential antitumor development candidate

Ansamycin-based Hsp90 inhibitor characterized by Conforma at AACR meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.